Galecto (NASDAQ: GLTO) to use January 2026 corporate presentation at J.P. Morgan conference

Rhea-AI Filing Summary

Galecto, Inc. reported that it plans to meet with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. During these meetings, the company expects to use a corporate slide presentation that is included as Exhibit 99.1, titled “Corporate Presentation (January 2026). The information related to these meetings and the presentation is being furnished under Regulation FD, meaning it is not treated as filed for purposes of the Securities Exchange Act of 1934 and is not subject to the associated liability provisions or automatically incorporated into other securities law filings.

0001800315false00018003152026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

GALECTO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39655		37-1957007
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

75 State Street, Suite 100

Boston, MA 02109

(Address of principal executive offices, including zip code)

(+45) 70 70 52 10

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		GLTO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 – Regulation FD Disclosure.

Galecto, Inc. (the “Company”) intends to conduct meetings with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. As part of these meetings, the Company intends to utilize the corporate slide presentation furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 hereto, is being furnished, not filed, pursuant to Regulation FD. Accordingly, The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Corporate Presentation (January 2026)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Galecto, Inc.
Date: January 12, 2026				By:		/s/ Sherwin Sattarzadeh
						Sherwin Sattarzadeh
						Chief Operating Officer

FAQ

What did Galecto, Inc. (GLTO) disclose in this 8-K?

Galecto, Inc. disclosed that it plans to meet with securities analysts, investors and others at the 44th Annual J.P. Morgan Healthcare Conference and will use a corporate slide presentation, furnished as Exhibit 99.1.

What is Exhibit 99.1 in Galecto, Inc.’s GLTO filing?

Exhibit 99.1 is Galecto, Inc.’s Corporate Presentation (January 2026), which the company intends to use in meetings during the J.P. Morgan Healthcare Conference.

How is the Galecto, Inc. (GLTO) presentation treated under securities laws?

The information in Item 7.01, including Exhibit 99.1, is being furnished, not filed under Regulation FD, so it is not deemed filed for Section 18 of the Exchange Act or automatically incorporated into other Securities Act or Exchange Act filings.

When does Galecto, Inc. plan to use this corporate presentation?

Galecto, Inc. plans to use the corporate presentation in meetings beginning on January 12, 2026, in connection with the 44th Annual J.P. Morgan Healthcare Conference.

Does this Galecto, Inc. (GLTO) 8-K include new financial results?

No financial statements or earnings data are included in this disclosure; it focuses on the planned use of a corporate presentation at an investor conference.

Who signed the Galecto, Inc. (GLTO) report?

The report was signed on behalf of Galecto, Inc. by Sherwin Sattarzadeh, the company’s Chief Operating Officer.